Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.67 |
| ▸ | CNR1 | P21554 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28396798 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2216579 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2217627 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL29511938 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL100166 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL3793537 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2342987 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL9243523 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL6417540 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2340727 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| CN-101909581-B | Sterol-modified amphiphilic lipids | UNIV CALIFORNIA | 2012-11-14 | — | — | CN | disclosed |
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-07-21 | — | — | US | disclosed |
| CN-101909581-A | Sterol-modified amphiphilic lipids | UNIV CALIFORNIA | 2010-12-08 | — | — | CN | disclosed |
| EP-2219587-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | The Regents of the University of California (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064696-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | SREBF1, SREBF2, SGMS1 | CNR2 1865/4885CNR1 1425/4885ALDH1A1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.